RF Acquisition Corp (RFAI) shareholders approved the business combination with Nanyang Biologics, triggering a nearly 500% after-hours stock surge. This approval marks a significant step towards the SPAC's de-SPAC transaction, transforming it into a biotech company.
RF Acquisition Corp (RFAI), a SPAC, announced that its shareholders approved the business combination with Singapore-based biotech Nanyang Biologics Pte. Ltd. This approval is a critical milestone for the SPAC, allowing it to complete its de-SPAC transaction and transition into an operating biotech company. The market reacted extremely positively, with the stock jumping nearly 500% after hours, indicating strong investor confidence in the merger and Nanyang Biologics' prospects. This event is a major short-term catalyst for RFAI, as the approval removes a significant hurdle for the merger's completion. Long-term implications will depend on Nanyang Biologics' performance post-merger. For traders, the immediate opportunity lies in the significant price movement, though volatility will be high.